Nathaniel Melling1, Kai Bachmann1, Bianca Hofmann1, Alexander Tarek El Gammal1, Matthias Reeh1, Oliver Mann1, Christoph Moebius2, Marco Blessmann2, Jakob Robert Izbicki1, Katharina Grupp3,4. 1. General-, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2. Department of Plastic-, Reconstructive and Aesthetic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. General-, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. k.grupp@uke.de. 4. Department of Plastic-, Reconstructive and Aesthetic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. k.grupp@uke.de.
Abstract
INTRODUCTION: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies. MATERIALS AND METHODS: This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens. RESULTS: While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225). CONCLUSIONS: In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.
INTRODUCTION: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies. MATERIALS AND METHODS: This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens. RESULTS: While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225). CONCLUSIONS: In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.
Authors: Mari C Vázquez-Borrego; Antonio C Fuentes-Fayos; Eva Venegas-Moreno; Esther Rivero-Cortés; Elena Dios; Paloma Moreno-Moreno; Ainara Madrazo-Atutxa; Pablo Remón; Juan Solivera; Luiz E Wildemberg; Leandro Kasuki; Judith M López-Fernández; Mônica R Gadelha; María A Gálvez-Moreno; Alfonso Soto-Moreno; Manuel D Gahete; Justo P Castaño; Raúl M Luque Journal: Cancers (Basel) Date: 2019-09-26 Impact factor: 6.639
Authors: Annette Salomonsson; Patrick Micke; Johanna S M Mattsson; Linnea La Fleur; Johan Isaksson; Mats Jönsson; Björn Nodin; Johan Botling; Mathias Uhlén; Karin Jirström; Johan Staaf; Maria Planck; Hans Brunnström Journal: Cancer Med Date: 2020-06-03 Impact factor: 4.452